Vaxinano, a Lille, France-based biotech company specializing in the development of prophylactic and therapeutic nasal vaccines, raised €6M in funding.
The round was led by TCD Capital, Captech Santé, Nord France Amorçage (NFA), Wiseed and a group of business angels, with additional support from BPI France.
The company intends to use the funds to accelerate its flagship vaccines and immuno-therapies targeting leishmaniasis, toxoplasmosis, and colibacillosis into clinical trials.
Led by CEO Jonathan Stauber, Vaxinano is a biotech company developing nasal vaccines to address unmet needs in infectious diseases. Its platform is based on an adjuvant-free formulation and offers high stability, enabling global distribution. In less than three years, it has developed versatile mucosal vaccines, both prophylactic and therapeutic, against zoonotic diseases such as leishmaniasis, toxoplasmosis and colibacillosis to protect humans, livestock, pets, and protected species through its WildVax conservation program.
FinSMEs
30/10/2024